# About Semaglutide Legit: An Independent Editorial Digest

> About Semaglutide Legit — an independent editorial project that publishes documentation-grade summaries of the peer-reviewed semaglutide research literature. Not a clinic, not a vendor.

Who publishes this digest, and the line it holds.

## What this site is

Semaglutide Legit is an independent editorial project that publishes summaries of the peer-reviewed research literature on semaglutide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "legit" in the name is an editorial position, not a service: it names a due-diligence register — a documentation-grade reading of what the published trial record actually establishes, and an equally plain reading of where the evidence stops or runs the other way. It does not claim that this site authenticates, certifies, sources, or supplies anything. The distinction matters: we read the literature; we do not stand between a reader and a product.

## How the digest is built

Each page is assembled from the published record — pivotal randomized trials, mechanism studies, pharmacokinetic analyses, and dedicated safety and pharmacovigilance reviews — and every quantitative claim is cited to a numbered source with a DOI or PubMed link. The editorial stance is documentation, not promotion: findings are staged by evidence strength, controlled-human-trial results are distinguished from preclinical or pharmacovigilance signals, and reported community experiences are clearly labelled as anecdotal rather than clinical evidence.

Where the literature is uncertain — the thyroid- and pancreatic-cancer signals, for instance — the digest says so rather than rounding the uncertainty away. Where a finding runs against the benefit, such as the SUSTAIN-6 retinopathy signal or post-discontinuation weight regain, it is surfaced as plainly as the benefits. Semaglutide is an approved medicine with an enormous quantitative evidence base; the job here is to read that base accurately, not to sell it.

## What this site is not

This site is not a source of medical advice, a prescriber, a pharmacy, or a vendor. It does not recommend doses for any individual; doses appear only as they were documented in published trials and approved labelling, in the third person. It does not evaluate, rank, or point to any commercial source of semaglutide, and it draws a clear line between the approved manufactured product — the basis of the trial evidence summarized here — and compounded or non-pharmaceutical preparations, which fall outside that evidence base. For anything concerning personal health, a qualified clinician is the right resource.

---

A documentation-grade reading of the semaglutide trial record — STEP, SUSTAIN, SELECT, FLOW, and the 2025 ESSENCE liver data — each finding versioned to its source and the approved-versus-compounded line drawn in full, by a publisher that prescribes nothing and sells nothing.